Clinical trials: Transmission
HIV Infections
Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
GLACIER (Giving Long Acting CABENUVA in an Infusion center/ASA) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting [LA] plus Rilpivirine LA) intramuscular (IM) in infusion centers/ASAs…
- Trial name
- GLACIER (NCT04982445)
- Testing
- CABENUVA
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
- Trial name
- NCT06061081
- Testing
- VH3739937
- Where
- 18 sites in United States, Argentina and 4 more
- Volunteers
- 21 people
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
The purpose of this study was to assess the safety and pharmacokinetics (PK) of three monoclonal antibodies, VRC01, VRC01LS, and VRC07-523LS, in HIV-exposed infants who are at increased risk of mother-to-child HIV transmission.
- Trial name
- NCT02256631
- Testing
- VRC01, VRC01LS, VRC07-523LS
- Where
- 14 sites in United States, Puerto Rico and 2 more
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Background: Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can treat vulvar HSIL.
- Conditions
- Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
- Trial name
- NCT03937791
- Testing
- E7 T Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, H1N1 Influenza Virus
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
Both pregnant women and people infected with HIV are at increased risk of viral infection, including influenza infection. Pregnant women infected with HIV may be at particular risk of infection from the new H1N1 influenza virus.
- Trial name
- NCT00992017
- Testing
- Influenza A (H1N1) monovalent vaccine
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
The purpose of this study is to determine the safety, toxicity, dosing, and antiviral effects of epigallocatechin gallate (EGCG) in capsule form (Polyphenon® E), administered orally twice daily at three different doses in…
- Trial name
- NCT01433289
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
HIV Infections
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 vaccines based on chimpanzee serotypes of adenovirus expressing clade C gp140 and a CH505TF gp120 protein boost in healthy, HIV- uninfected adult…
- Trial name
- HVTN139 (NCT05182125)
- Testing
- AdC6-HIVgp140, AdC7-HIVgp140, CH505TF gp120
- Where
- 6 sites in South Africa
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Methamphetamine Abuse, HIV
Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM
Participants receive culturally relevant and specifically tailored text messages based on the behavioral change theoretical constructs of Social Support Theory, Health Belief Model, and Social Cognitive Theory.
- Trial name
- NCT02008526
- Testing
- Text Messages Transmitted by Peer Health Educators (TXT-PHE), Text Messages Transmitted by Automation (TXT-Auto)
- Where
- United States
- Volunteers
- 286 people
- Sponsor
- Friends Research Institute, Inc.
HIV Infection
HIV and Fat Accumulation
This is a research study to see whether fat accumulation either under the skin or in the body's organs, for example, the liver, improves in men and women who take a drug called telmisartan.
- Trial name
- MATH (NCT01088295)
- Testing
- Telmisartan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Los Angeles
HIV Infections
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing highly active antiretroviral therapy (HAART)…
- Trial name
- TOTEM (NCT00323492)
- Testing
- Truvada, Current HAART regimen
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Acquired Immunodeficiency Syndrome, HIV Infections
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
This study is to characterize the effect of cobicistat-based regimens on parameters of renal function in participants with HIV infection and who have mild to moderate renal impairment, and to assess the safety and tolerability of…
- Trial name
- NCT01363011
- Testing
- E/C/F/TDF, COBI, ATV
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs…
- Trial name
- NCT01482767
- Testing
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 262 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Urethritis, Cervicitis
Rapid Diagnostic Assay for Gonorrhea and Chlamydia
This study is a pilot randomized controlled trial evaluating the use of either a) rapid 30-minute desktop assay or b) point-of-care gram stain (current standard of care) to guide the clinical management of patients with…
- Conditions
- Urethritis, Cervicitis, Sexually Transmitted Infections
- Trial name
- NCT05564299
- Testing
- Rapid 30-minute Desktop Assay
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Massachusetts General Hospital
HIV Infections
Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial
YouTHrive (YT) is a two-arm randomized control trial (RCT) to test the efficacy of an adapted version of the Thrive With Me (TWM) intervention for youth living with HIV (YLWH).
- Trial name
- NCT03149757
- Testing
- YouTHrive, Information-only Control
- Where
- 7 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
HIV
PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV
The purpose of this study is to determine whether the use of rectal lubricants can affect how well the medication, Truvada, will work to prevent infection with HIV when someone is exposed to HIV in the rectum.
- Trial name
- NCT02401230
- Testing
- Truvada, Gel lubricant
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Emory University
Human Immunodeficiency Virus
Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk
This cluster randomized trial will assess whether the provision of multiple oral-fluid based HIV self-test kits to HIV-negative women at high risk of acquiring HIV in western Kenya is an approach that promotes HIV testing among…
- Trial name
- NCT03135067
- Testing
- Provision of multiple self-tests
- Where
- Kenya
- Volunteers
- 2,102 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hepatitis C, Chronic, Hepacivirus
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy.
- Conditions
- Hepatitis C, Chronic, Hepacivirus, HIV Infections
- Trial name
- NCT00687544
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults.
- Trial name
- NCT05163522
- Testing
- VH4004280, Midazolam
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Obesity, Obesity, Childhood
In-home Obesity Prevention to Reach Low-income Infants
Existing obesity prevention efforts have had limited success among underserved, low-income children. This study capitalizes on the strengths of a nationwide ongoing Home Visitation Program (HVP), which serves at-risk, low-income…
- Conditions
- Obesity, Obesity, Childhood, Obesity; Familial
- Trial name
- NCT03529695
- Testing
- Standard HVP Curriculum, Obesity Prevention
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.